BioSpace News Archive

Ridgeback Biotherapeutics LP, a closely held biotechnology company provides an update on mAb114, an experimental treatment for Ebola.

TerrAscend Corp. (CSE: TER; OTCQX: TRSSF) (“TerrAscend” or “the Company”), today announced that it will release its second quarter 2019 financial results on Thursday, August 22nd, 2019 at approximately 8:00 a.m. (ET).

Conagen, a Boston-based biotechnology company focusing on research and development, announced today its breakthrough development in the commercial production of natural aromatic compound, γ-Decalactone from natural substrates using its proprietary technology.

Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of targeted immunotherapies using fully human monoclonal antibodies (mAbs) to treat life-threatening bacterial infections, today reported financial and corporate results for the second quarter ended June 30, 2019.

The Company intends to release its preliminary revenue and to file an 8-K/A including pro forma financials associated with its acquisition of Ross Optical Industries

Portola Pharmaceuticals, Inc.® announced plans to offer, subject to market and other conditions, $200 million of its common stock in an underwritten public offering.

The 2019 Community Health Institute and EXPO, hosted by the National Association of Community Health Centers, will kick off the week of August 18-20.

Phio Pharmaceuticals Corp., a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi therapeutic platform, reported its financial results for the second quarter ended June 30, 2019, and provided a business update.

Axcella Health Inc. announced financial results for the second quarter ended June 30, 2019 and provided a company update.

AAC Holdings, Inc. announced preliminary estimated operational and financial results for the second quarter ended June 30, 2019.